Genix Pharmaceuticals (TSXV:GENX) LT-Debt-to-Total-Asset : 0.00 (As of Jan. 2025)

View and export this data going back to 1999. Start your Free Trial

What is Genix Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Genix Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jan. 2025 was 0.00.

Genix Pharmaceuticals's long-term debt to total assets ratio stayed the same from Jan. 2024 (0.00) to Jan. 2025 (0.00).

Genix Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Genix Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genix Pharmaceuticals LT-Debt-to-Total-Asset Chart

Genix Pharmaceuticals Annual Data

Trend

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Genix Pharmaceuticals Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Genix Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Genix Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Oct. 2024 is calculated as

LT Debt to Total Assets (A: Oct. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Oct. 2024 )	/	Total Assets (A: Oct. 2024 )
	=	0	/	0.046
	=	0.00

Genix Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2025 is calculated as

LT Debt to Total Assets (Q: Jan. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2025 )	/	Total Assets (Q: Jan. 2025 )
	=	0	/	0.056
	=

Genix Pharmaceuticals (TSXV:GENX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Genix Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Genix Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Genix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genix Pharmaceuticals Corp (TSXV:GENX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8

Website

https://www.genixpharm.com

Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically, the company operates only in Canada.

Executives

Sina Pirooz	Director
Paul Chow	10% Security Holder, Director
Jamie A. Lewin	Director

Genix Pharmaceuticals Headlines

No Headlines